Last reviewed 2026-04-23 · How we verify

GC FLU inj.

GC FLU is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.

GC FLU is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.

At a glance

Mechanism of action

The vaccine contains inactivated (killed) influenza virus particles or viral components that trigger both humoral and cellular immune responses. Upon administration, the immune system recognizes these antigens and generates protective antibodies and memory cells, reducing the risk of infection and severity of disease if exposure to wild-type influenza occurs.

Approved indications

• Seasonal influenza prevention in adults and children

Common side effects

• Injection site pain or erythema
• Myalgia
• Headache
• Low-grade fever

Key clinical trials

• To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults (PHASE3)
• A Multicenter, Double-blind, Parallel Phase III Study (PHASE3)
• Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine) (PHASE1, PHASE2)
• A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GC FLU inj. CI brief — competitive landscape report
• GC FLU inj. updates RSS · CI watch RSS
• Green Cross Corporation portfolio CI